SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-048329
Filing Date
2024-04-25
Accepted
2024-04-25 16:15:26
Documents
48
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q abio-20240331.htm   iXBRL 10-Q 1197520
2 EX-31.1 abio-ex31_1.htm EX-31.1 11214
3 EX-31.2 abio-ex31_2.htm EX-31.2 11082
4 EX-32.1 abio-ex32_1.htm EX-32.1 13361
  Complete submission text file 0000950170-24-048329.txt   4188544

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT abio-20240331.xsd EX-101.SCH 715977
51 EXTRACTED XBRL INSTANCE DOCUMENT abio-20240331_htm.xml XML 439070
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 24876502
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)